AdvanCell

About AdvanCell

AdvanCell is a vertically integrated, clinical stage radiopharmaceutical company focused on developing novel targeted alpha therapies to improve survival and quality of life for patients with cancer.

Products & Services

Targeted Alpha Therapies:A portfolio of therapies for treating various cancers including prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary.

Alpha 212:A quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API), produced by AdvanCell’s proprietary ²¹²Pb generator, manufactured to international GMP standards.

Specialties

Targeted Alpha Therapies ²¹²Pb Production Technology Cancer Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 18000000 MR: - FA: $18M FAN: 18000000	D: 2025-04-13 FD: 2025-04-13	1 investors
2	RT: Series C T: - FT: Series C	A: 112000000 MR: - FA: US$112 million FAN: 112000000	D: 2025-02-03 FD: 2025-02-03	7 investors

Grant Latest

2025-04-13

$18.0M

1 investor (Pro only)

Series C 2025-02-03

$112.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Andrew Adamovich

Founder and Director

S

Simon Puttick

Chief Scientific Officer and Chief Technology Officer

A

Anna Karmann

Chief Medical Officer

M

Matthew Vincent

Chief Business Officer

G

Gary Li

Chief Strategy Officer

D

Dayle Hogg

Chief Operating Officer (Consulting)

View 28 more team members with Pro

Unlock Full Team Directory

Recent News

AdvanCell Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised